D. Ackermann

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA.

Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ.

Tangible Science, Inc. manufactures contact lenses and provides eye care services. It develops a novel polymer based coating technology for use in contact lenses to treat dry eye disease. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Karen Havenstrite, Victor W. McCray, and Garrett Cale Smith in 2011 and is headquartered in Redwood City, CA.

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

Vensana Capital Management LLC (Vensana Capital) is a venture capital and growth equity investment firm founded in 2019 by Peter Klein Justin & Kirk G. Nielsen. The firm is headquartered in Saint Paul, Minnesota.

Presidio Medical, Inc. operates as a bioelectronic medicine firm. It develops fundamental neuromodulation platform to establish a new class of therapeutic medical devices. The company was founded by Kenneth Wu on November 14, 2018 and is headquartered in Carson City, NV.

Stanford Byers Center for Biodesign is a private company committed to advancing health outcomes and equity through innovation education, translation, and policy. More than 4.3 million people have been helped by technologies invented at Stanford Biodesign, and the biodesign innovation process has been widely adopted by universities and training programs around the world. The American company believes that diversity across multiple dimensions inspires creativity and helps them innovate for all patient populations. The company was founded by Joshua Makower and Paul G. Yock in 2001 at Stanford.